MedTrace Logo

A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis

NCT00540618 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2007-11-28

No results posted yet for this study

Summary

To compare disease activity, as measured by PASI score, of three MEDI-507 dosing (injection)regimens vs. placebo.

Conditions

Interventions

DRUG

MEDI-507

Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)

OTHER

Placebo

DRUG

MEDI-507

Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)

DRUG

MEDI-507

Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • Christine A Dingivan, M.D. · MedImmune LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Completion
2003-07-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00540618 on ClinicalTrials.gov